Market closed
Rhythm Pharmaceuticals/$RYTM
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
Ticker
$RYTM
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
226
Website
RYTM Metrics
BasicAdvanced
$3.4B
Market cap
-
P/E ratio
-$4.33
EPS
2.09
Beta
-
Dividend rate
Price and volume
Market cap
$3.4B
Beta
2.09
52-week high
$65.17
52-week low
$35.17
Average daily volume
601K
Financial strength
Current ratio
3.487
Quick ratio
3.255
Long term debt to equity
74.181
Total debt to equity
74.181
Interest coverage (TTM)
-13.47%
Management effectiveness
Return on assets (TTM)
-46.24%
Return on equity (TTM)
-147.90%
Valuation
Price to revenue (TTM)
30.123
Price to book
307.43
Price to tangible book (TTM)
714.28
Price to free cash flow (TTM)
-20.554
Growth
Revenue change (TTM)
81.55%
Earnings per share change (TTM)
32.93%
3-year revenue growth (CAGR)
338.24%
3-year earnings per share growth (CAGR)
49.92%
What the Analysts think about RYTM
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Rhythm Pharmaceuticals stock.
RYTM Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RYTM Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RYTM News
AllArticlesVideos
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential
Benzinga·2 days ago
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old
GlobeNewsWire·2 days ago
Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Rhythm Pharmaceuticals stock?
Rhythm Pharmaceuticals (RYTM) has a market cap of $3.4B as of December 22, 2024.
What is the P/E ratio for Rhythm Pharmaceuticals stock?
The price to earnings (P/E) ratio for Rhythm Pharmaceuticals (RYTM) stock is 0 as of December 22, 2024.
Does Rhythm Pharmaceuticals stock pay dividends?
No, Rhythm Pharmaceuticals (RYTM) stock does not pay dividends to its shareholders as of December 22, 2024.
When is the next Rhythm Pharmaceuticals dividend payment date?
Rhythm Pharmaceuticals (RYTM) stock does not pay dividends to its shareholders.
What is the beta indicator for Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals (RYTM) has a beta rating of 2.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.